Also trades as: 1801.HK (HKSE) · $vol 173M
IVBXF OTC
Innovent Biologics, Inc.
1W: +2.8%
1M: -0.3%
3M: +9.6%
YTD: +18.3%
1Y: +4.7%
3Y: +260.6%
5Y: +7.6%
$12.80
+0.29 (+2.33%)
Weekly Expected Move ±14.3%
$9
$11
$13
$15
$16
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Balance Sheet Trends
Total Assets
$37.4B
+73.0% ▲
5Y CAGR: +25.9%
Total Liabilities
$17.2B
+102.7% ▲
5Y CAGR: +41.3%
Shareholders Equity
$19.4B
+47.6% ▲
5Y CAGR: +17.1%
Cash & Investments
$18.2B
+131.4% ▲
5Y CAGR: +17.6%
Total Debt
$2.8B
-0.5% ▼
5Y CAGR: +18.5%
Net Debt
-$14.5B
-210.8% ▼
Assets vs Liabilities & Equity
Year-over-Year Growth
View Full Balance Sheet
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Assets — | |||||
| Cash | $1.4B | $1.0B | $10.1B | $7.5B | $17.4B |
| Short-Term Investments | $6.6B | $7.2B | $868M | $376M | $887M |
| Cash & ST Investments | $9.0B | $9.2B | $11.0B | $7.9B | $18.2B |
| Net Receivables | $1.2B | $912M | $1.0B | $1.6B | $1.8B |
| Inventory | $1.3B | $1.4B | $968M | $822M | $1.3B |
| Other Current Assets | $7M | $0 | $484M | $0 | $729M |
| Total Current Assets | $11.6B | $11.5B | $13.4B | $10.3B | $22.0B |
| Property, Plant & Equip. | $3.4B | $4.1B | $4.7B | $5.6B | $5.4B |
| Goodwill & Intangibles | $772M | $1.2B | $28M | $1.3B | $1.5B |
| Long-Term Investments | -$6.2B | $630M | $794M | $3.9B | $7.9B |
| Other Non-Current Assets | $6.7B | $193M | $1.7B | $499M | $471M |
| Total Non-Current Assets | $4.7B | $6.1B | $7.2B | $11.3B | $15.3B |
| Total Assets | $16.2B | $17.6B | $20.6B | $21.6B | $37.4B |
| — Liabilities — | |||||
| Accounts Payable | $195M | $326M | $373M | $358M | $495M |
| Short-Term Debt | $365M | $888M | $1.2B | $405M | $801M |
| Deferred Revenue | $0 | $0 | $0 | $0 | $2.3B |
| Other Current Liabilities | $790M | $742M | $728M | $2.3B | $4.8B |
| Total Current Liabilities | $3.1B | $3.5B | $4.5B | $4.4B | $8.4B |
| Long-Term Debt | $2.0B | $2.2B | $2.3B | $2.4B | $2.0B |
| Other Non-Current Liab. | $342K | $162M | $263M | $1.7B | $643M |
| Total Non-Current Liabilities | $2.9B | $3.4B | $3.6B | $4.1B | $8.8B |
| Total Liabilities | $5.9B | $6.9B | $8.1B | $8.5B | $17.2B |
| — Equity — | |||||
| Common Stock | $101K | $105K | $112K | $113K | $119K |
| Retained Earnings | -$12.6B | -$14.7B | -$15.8B | -$15.9B | $0 |
| Accumulated OCI | $397M | $764M | $971M | $1.3B | $0 |
| Total Stockholders Equity | $10.3B | $10.7B | $12.5B | $13.1B | $19.4B |
| Total Liabilities & Equity | $16.2B | $17.6B | $20.6B | $21.6B | $37.4B |
| — Key Metrics — | |||||
| Total Debt | $2.5B | $3.2B | $3.6B | $2.8B | $2.8B |
| Net Debt | $1.1B | $2.2B | -$6.4B | -$4.7B | -$14.5B |
| Total Investments | $417M | $7.9B | $1.7B | $4.3B | $8.8B |